Author: Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L
Year: 2017
AGREE II score: Available
Developer organization: International Pediatric Fever and Neutropenia Guideline Panel
Type of cancer: Hematological, Not disease site specific
Patient population: Pediatric
Location: International
This is a clinical practice guideline for the empirical management of fever and neutropenia (FN) in children with cancer, and those who have received hematopoietic stem-cell transplantation (HSCT). The guideline examines initial presentation, ongoing management, and empirical antifungal therapy. Topics of interest include risk stratification to define patients with high-risk invasive fungal disease (IFD), recommended biomarkers and radiologic investigations for the evaluation of IFD in prolonged FN, and empirical antifungal therapy in IFD low-risk patients with prolonged FN.
AGREE II - Quality of Reporting Assessment:
Scope and purpose: 88.9%
Applicability: 45.8%
Stakeholder involvement: 50%
Editorial independence: 83.3%
Rigour: 61.5%
Clarity presentation: 88.9%
